MA42616A - Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire - Google Patents

Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire

Info

Publication number
MA42616A
MA42616A MA042616A MA42616A MA42616A MA 42616 A MA42616 A MA 42616A MA 042616 A MA042616 A MA 042616A MA 42616 A MA42616 A MA 42616A MA 42616 A MA42616 A MA 42616A
Authority
MA
Morocco
Prior art keywords
etc1002
ezetimibe
risk
treating
reducing
Prior art date
Application number
MA042616A
Other languages
English (en)
Inventor
Diane Elaine Macdougall
Roger Schofield Newton
Noah Laban Rosenberg
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56920255&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42616(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of MA42616A publication Critical patent/MA42616A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA042616A 2015-03-13 2016-03-14 Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire MA42616A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562133128P 2015-03-13 2015-03-13
US201562250921P 2015-11-04 2015-11-04

Publications (1)

Publication Number Publication Date
MA42616A true MA42616A (fr) 2021-05-19

Family

ID=56920255

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042616A MA42616A (fr) 2015-03-13 2016-03-14 Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire

Country Status (18)

Country Link
US (2) US10912751B2 (fr)
EP (1) EP3267989A4 (fr)
JP (2) JP6940411B2 (fr)
KR (1) KR102370582B1 (fr)
CN (2) CN107530307A (fr)
AU (3) AU2016233485B2 (fr)
BR (1) BR112017019358A2 (fr)
CA (1) CA2978204A1 (fr)
CL (1) CL2017002299A1 (fr)
IL (1) IL254194A0 (fr)
MA (1) MA42616A (fr)
MX (2) MX2017011499A (fr)
PH (1) PH12017501625A1 (fr)
RU (2) RU2022102472A (fr)
SG (2) SG10201908500UA (fr)
UA (1) UA123355C2 (fr)
WO (1) WO2016149191A1 (fr)
ZA (1) ZA201706919B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017011499A (es) 2015-03-13 2018-03-26 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
JP2020506241A (ja) * 2017-02-08 2020-02-27 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
WO2019179494A1 (fr) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 Composé d'acide pentadécanedioïque substitué, composition pharmaceutique et utilisation associée
EP3844168A4 (fr) * 2018-08-27 2022-05-18 Esperion Therapeutics, Inc. Préparations médicamenteuses combinées pour le traitement de patients atteints d'une maladie cardiovasculaire et d'états pathologiques associés
BR112021025964A2 (pt) 2019-06-21 2022-05-24 Esperion Therapeutics Inc Formas de sal de ácido bempedoico e métodos para uso das mesmas
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物
US20240226049A1 (en) * 2023-01-09 2024-07-11 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1304093A (en) 1919-05-20 Camera
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
US3441605A (en) 1965-02-17 1969-04-29 Wallace & Tiernan Inc Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
FR1545224A (fr) 1966-12-21 1968-11-08 Geigy Ag J R Procédé de préparation de l'acide sébacique
GB1196597A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of an Oxido-Cyclodecene
GB1196596A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a hydroxysebacic acid
GB1196595A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Lactone
GB1196598A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Ketosebacic Acid
GB1196594A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Improvements in and relating to the production of Sebacic Acid
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4281200A (en) 1979-08-30 1981-07-28 The Dow Chemical Company Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en) 1979-09-04 1981-04-14 Kao Corp Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (it) 1983-05-30 1987-04-08 Luso Farmaco Inst 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione
JPS59232811A (ja) 1983-06-16 1984-12-27 Sumitomo Chem Co Ltd 芳香族ポリアミドイミド樹脂成形体の製造方法
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4896344A (en) 1984-10-15 1990-01-23 Grady John K X-ray video system
US4634119A (en) 1985-07-11 1987-01-06 Pesthy Paul K Resilient exercise machine with body support platform
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Ｄｎａおよびその用途
US5254589A (en) 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5420339A (en) 1993-11-22 1995-05-30 Warner-Lambert Company Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (ja) 1994-04-08 1999-08-23 時久 増田 角筒包装袋の製造方法及び装置
US5578639A (en) 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5504073A (en) 1994-07-01 1996-04-02 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
ATE348607T1 (de) 1995-11-02 2007-01-15 Warner Lambert Co Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en) 1997-04-21 2000-07-25 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
IL135154A (en) 1997-11-25 2005-05-17 Warner Lambert Co Inhbition of lipoprotein oxidation
ES2244238T3 (es) 1998-12-07 2005-12-01 Schering Corporation Proceso para la sintesis de azetidinonas.
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
CN1329359C (zh) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1351916A2 (fr) 2000-10-11 2003-10-15 Esperion Therapeutics Inc. Composes d'ether et compositions pour la gestion du cholesterol et utilisations associees
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2425674A1 (fr) 2000-10-11 2002-04-18 Jean-Louis H. Dasseux Composes et compositions de sulfure et de disulfure pour le traitement du cholesterol et utilisations associees
EP1326822A2 (fr) 2000-10-11 2003-07-16 Esperion Therapeutics Inc. Composes de fonction cetone et compositions pour la regulation du taux de cholesterol, et utilisations associees
CA2425678A1 (fr) 2000-10-11 2002-04-18 Jean-Louis H. Dasseux Composes de sulfoxyde et de bis-sulfoxyde et compositions pour reguler le cholesterol, et applications associees
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
EP2404890B1 (fr) 2003-01-23 2017-07-26 Esperion Therapeutics Inc. Composés hydroxyle et compositions pour la gestion du cholestérol et utilisations associées
US20050171080A1 (en) 2003-12-23 2005-08-04 Dr. Reddy's Laboratories, Inc. Polymorphs of ezetimibe and process for preparation thereof
JP2007525408A (ja) 2003-12-24 2007-09-06 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連使用のためのケトン化合物および組成物
JP4553181B2 (ja) 2004-03-25 2010-09-29 株式会社サタケ 残留農薬分析方法
US7194579B2 (en) 2004-04-26 2007-03-20 Sun Microsystems, Inc. Sparse multi-component files
AR057575A1 (es) 2005-11-15 2007-12-05 Takeda Pharmaceutical Metodo para tratar hiperlipidemia
BRPI0809320A2 (pt) 2007-03-24 2014-09-23 Genzyme Corp Método
US8209479B2 (en) 2007-07-18 2012-06-26 Google Inc. Memory circuit system and method
UA103179C2 (ru) 2007-12-10 2013-09-25 Ратиофарм Гмбх Фармацевтическая композиция, которая содержит эзетимиб
EP2168573A1 (fr) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations contentant d'ézétimibe
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
EP2229938B9 (fr) 2009-03-13 2012-04-25 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions d'ézétimibe
CA2812109A1 (fr) 2010-09-20 2012-03-29 Kareus Therapeutics, Sa Procedes et compositions pour le traitement du diabete et de la dyslipidemie
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
AR086675A1 (es) 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
CN111789944A (zh) * 2011-09-16 2020-10-20 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
EP3735967A1 (fr) * 2012-01-06 2020-11-11 NeuroBo Pharmaceuticals, Inc. Composé destiné à être utilisé dans des procédés permettant de réduire le risque d'une maladie cardiovasculaire
MX2014011815A (es) 2012-04-18 2014-12-05 Mallinckrodt Llc Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9527838B2 (en) 2012-12-17 2016-12-27 Merck Sharp & Dohme Corp. 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
MX2017011499A (es) 2015-03-13 2018-03-26 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (fr) 2015-08-04 2017-02-09 Dezima Pharma B.V. Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et d'un inhibiteur de citrate lyase d'atp–activateur d'ampk
JP2020506241A (ja) 2017-02-08 2020-02-27 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
CA3110346A1 (fr) 2018-08-24 2020-02-27 Esperion Therapeutics, Inc. Procedes de reduction du risque de diabete chez des patients traites pour des maladies associees a un taux eleve de cholesterol
EP3844168A4 (fr) 2018-08-27 2022-05-18 Esperion Therapeutics, Inc. Préparations médicamenteuses combinées pour le traitement de patients atteints d'une maladie cardiovasculaire et d'états pathologiques associés

Also Published As

Publication number Publication date
SG11201707497UA (en) 2017-10-30
EP3267989A1 (fr) 2018-01-17
MX2022005469A (es) 2022-06-02
UA123355C2 (uk) 2021-03-24
RU2017136180A (ru) 2019-04-15
KR20180006887A (ko) 2018-01-19
IL254194A0 (en) 2017-10-31
AU2024202106A1 (en) 2024-05-02
AU2016233485A1 (en) 2017-11-02
BR112017019358A2 (pt) 2018-05-08
CL2017002299A1 (es) 2018-03-16
US10912751B2 (en) 2021-02-09
JP6940411B2 (ja) 2021-09-29
US11744816B2 (en) 2023-09-05
KR102370582B1 (ko) 2022-03-04
JP7295179B2 (ja) 2023-06-20
US20180064671A1 (en) 2018-03-08
AU2021218120A1 (en) 2021-09-09
ZA201706919B (en) 2022-03-30
RU2022102472A (ru) 2022-03-15
SG10201908500UA (en) 2019-11-28
PH12017501625A1 (en) 2018-02-12
US20210361605A1 (en) 2021-11-25
CN107530307A (zh) 2018-01-02
JP2021193105A (ja) 2021-12-23
AU2016233485B2 (en) 2021-05-20
MX2017011499A (es) 2018-03-26
RU2017136180A3 (fr) 2019-09-19
RU2766085C2 (ru) 2022-02-07
JP2018507901A (ja) 2018-03-22
WO2016149191A1 (fr) 2016-09-22
CN114099496A (zh) 2022-03-01
CA2978204A1 (fr) 2016-09-22
EP3267989A4 (fr) 2018-11-07

Similar Documents

Publication Publication Date Title
MA42616A (fr) Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire
HK1251257A1 (zh) 用於醫治疾病的外泌體的用途
MA50056A (fr) Procédés de traitement de tumeur
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
EP3319976A4 (fr) Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
MA47613A (fr) Compositions et procédés de traitement du cancer
MA43129A (fr) Procédés de traitement de la douleur ou de la fièvre au moyen de dimères d'acétaminophène pharmaceutiquement actifs liés par l'intermédiaire de groupes hydroxyle phénoliques
HK1252813A1 (zh) 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
DK3236983T3 (da) Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet
BR112017005713A2 (pt) composto da fórmula (i), método de mobilização das células-tronco hematopoiéticas (hsc) e células progenitoras endoteliais (epc) na circulação periférica, método de tratamento de lesão tecidual, câncer, doença inflamatória ou doença autoimune, e composição farmacêutica
MA42936A (fr) Procédé de traitement de blessures cardiaques
GB2561747B (en) Composition for treating motor neuron diseases and use thereof
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
DK3307277T3 (da) Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
MA41090A (fr) Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
MA51295A (fr) Dosage, procédé et traitement d'alpha-synucléinopathies
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines
HK1258999A1 (zh) 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物
MA46970A (fr) Procédés de traitement de la maladie polykystique des reins